Frauenheilkunde up2date, Table of Contents Frauenheilkunde up2date 2008; 2(05): 395-422DOI: 10.1055/s-2008-1077009 Allgemeine Gynäkologie und gynäkologische Onkologie Zervixkarzinom C. Köhler , A. Schmittel , A. M. Kaufmann , C. Schreckenberger , S. Marnitz Recommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Parkin DM, Bray F, Ferlay J. et al Global cancer statistics, 2002.. CA Cancer J Clin 2005; 55: 74-108 2 Robert-Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.. Hrsg Krebs in Deutschland 2003–2004. Häufigkeiten und Trends.. 6. überarb. Aufl. Berlin; 2008 3 Statistisches Bundesamt. Gesundheitsberichterstattung, Todesursachenstatistik.. www.gbe-bund.de, Abfrage: 18.7.2008 4 zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application.. Nat Rev Cancer 2002; 2: 342-350 5 Walboomers JM, Jacobs MV, Manos MM. et al Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.. J Pathol 1999; 189: 12-12 6 Munoz N, Bosch FX, de Sanjose S. et al Epidemiologic classification of human papillomavirus types associated with cervical cancer.. N Engl J Med 2003; 348: 518-527 7 Clifford GM, Smith JS, Plummer M. et al Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis.. Br J Cancer 2003; 88: 63-73 8 Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections.. J Clin Virol 2005; 32: S16-S24 9 Villa LL, Costa RL, Petta CA. et al Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised doubleblind placebo-controlled multicentre phase II efficacy trial.. Lancet Oncol 2005; 6: 271-278 10 Villa LL, Costa RL, Petta CA. et al High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6 / 11 / 16 / 18 L1 virus-like particle vaccine through 5 years of follow-up.. Br J Cancer 2006; 95: 1459-1466 11 Garland SM, Hernandez-Avila M, Wheeler CM. et al for the Females United to Unilaterally Reduce Endo / Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.. N Engl J Med 2007; 356: 1928-1943 12 FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.. N Engl J Med 2007; 356: 1915-1927 13 Fachinformation Gardasil.. Merck C., inc., Whitehouse station, NJ 08889, USA; 2006 14 Harper DM, Franco EL, Wheeler C. et al Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.. Lancet 2004; 364: 1757-1765 15 Harper DM, Franco EL, Wheeler CM. et al Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.. Lancet 2006; 367: 1247-1255 16 Wheeler CM, Teixeira J, Romanowski B. et al High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix™ (GSK HPV-16 / 18 AS04 vaccine). ESPID (European Society for Paediatric Infectious Diseases. Graz, Austria: May 13–17; 2008) 17 Press release EMEA: statement on the safety of Gardasil.. London: January 24; 2008 (www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/Gardasil_press_release.pdf 18 Villa LL, Ault KA, Giuliano AR. et al Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18.. Vaccine 2006; 24: 5571-5583 19 Carter JJ, Koutsky LA, Hughes JP. et al Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.. J Infect Dis 2000; 181: 1911-1919 20 Viscidi RP, Schiffman M, Hildesheim A. et al Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31, and risk of subsequent HPV infection: results from a populationbased study in Costa Rica.. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-327 21 Gall SA, Teixeira J, Wheeler CM. et al Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16 / 18 L1 VLP AS04 candidate vaccine. Presented at American Association for Cancer Research (AACR). Los Angeles, CA, USA: April 14–18; 2007 22 Paavonen J, Jenkins D, Bosch FX. et al HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.. Lancet 2007; 369: 2161-2170 Erratum in: Lancet 2007; 370: 1414 23 Brown D. HPV Type 6 / 11 / 16 / 18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16 / 18. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA: 17–20 September; 2007 24 Robert-Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung.. Epidemiologisches Bulletin 2007; 12: 97-103 25 Pathirana D. für das HPV Management Forum. S3-Leitfür das HPV Management Forumlinie zur Impfprävention HPV-assoziierter Neoplasien.. Chemotherapie Journal 2008; 17: 120-171 26 Luna J, Saah A, Hood S. et al Safety, efficacy, and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24–45.. 24th International Papillomavirus Congress: Beijing, China: November 3–9; 2007 27 Schwarz TF, Dubin G. the HPV Vaccine Study Investigators for Adult Women. Human papillomavirus (HPV) 16 / 18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years (Abstract 3007).. J Clin Oncol 2007 2007; 25 ASCO Annual Meeting Proceedings Part I 28 Wright TCJr, Huh WK, Monk BJ. et al Age considerations when vaccinating against HPV.. Gynecol Oncol 2008; 109: 40-47 29 Gross G. Für das Deutsche HPV-Management-Forum Wer sollte wann, wo und wie geimpft werden? Antworten des HPV-Management-Forums auf viel diskutierte Fragen, die mit Einführung von zwei unterschiedlichen HPV-Impfstoffen zur Prävention des Zervixkarzinoms und der Condylomata acuminata in Zusammenhang stehen.. Dtsch Ärzteblatt 2006; 103: 3384-3388 30 Schneider A, Schwarz TF, Hammerschmidt T. et al Einfluss einer Impfung gegen humane Papillomviren auf die Inzidenz und Mortalität von Zervixkarzinom in Deutschland.. Med Klin 2007; 102: 515-523 31 Altenhofen L. 2005 Hochrechnung zur Akzeptanz von Gesundheitsuntersuchungen und Krebsfrüherkennungsuntersuchungen bei gesetzlich Versicherten.. Berlin: Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland 32 Peto J, Gilham C, Fletcher O. et al The cervical cancer epidemic that screening has prevented in the UK.. Lancet 2004; 364: 249-956 33 Kaufmann AM, Schneider A. Therapeutic human papillomavirus vaccination.. Therapy 2008; 5: 339-348 34 Hertel H, Köhler C, Elhawary T. et al Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer.. Gynecol Oncol 2002; 87: 46-52 35 Hricak H, Gatsonis C, Coakley FV. et al Early invasive cervical cancer: CT and MR imaging in preoperative evaluation – ACRIN / GOG comparative study of diagnostic performance and interobserver variability.. Radiology 2007; 245: 491-498 36 Sironi S, Buda A, Picchio M. et al Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG- PET / CT.. Radiology 2006; 238: 272-279 37 Yildirim Y, Sehirali S, Avci ME. et al Integrated PET / CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.. Gynecol Oncol 2008; 108: 154-159 38 Loft A, Berthelsen AK, Roed H. et al The diagnostic value of PET / CT scanning in patients with cervical cancer: a prospective study.. Gynecol Oncol 2007; 106: 29-34 39 Choi HJ, Roh JW, Seo SS. et al Comparison of the accuracy of magnetic resonance imaging and positron emission tomography / computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study.. Cancer 2006; 106: 914-922 40 Fagotti A, Fanfani F, Longo R. et al Which role for pretreatment laparoscopic staging?. Gynecol Oncol 2007; 107: 101-105 41 Ayhan A, Al RA, Baykal C. et al A comparison of prognoses of FIGO stage I B adenocarcinoma and squamous cell carcinoma.. Int J Gynecol Cancer 2004; 14: 279-285 42 Singh N, Arif S. Histopathologic parameters of prognosis in cervical cancer–a review.. Int J Gynecol Cancer 2004; 14: 741-750 43 Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?. Gynecol Oncol 2004; 92: 525-529 44 Lai CH, Huang KG, Hong JH. et al Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer.. Gynecol Oncol 2003; 89: 160-167 45 Vidauretta J, Bermudez A, di Oaola G. et al Laparoscopic staging in locally advanced cervical carcinoma: a new possible philosophy?. Gynecol Oncol 1999; 75: 366-371 46 Marnitz S, Köhler C, Roth C. et al Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.. Strahlenther Onkol 2007; 183: 473-478 47 Leblanc E, Narducci F, Frumovitz M. et al Therapeutic value of pretherapeutic extraperitoneal laparoscopic staging of locally advanced cervical carcinoma.. Gynecol Oncol 2007; 105: 304-311 48 Tillmanns T, Lowe MP. Safety, feasibility and costs of outpatient laparoscopic extraperitoneal aortic nodal dissection for locally advanced cervical carcinoma.. Gynecol Oncol 2007; 106: 370-374 49 Marnitz S, Köhler C, Roth C. et al Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer?. Gynecol Oncol 2005; 99: 536-544 50 Hertel H, Köhler C, Grund D. et al Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer.. Gynecol Oncol 2006; 103: 506-511 51 Plante M, Renaud MC, Francois H. et al Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature.. Gynecol Oncol 2004; 94: 614-623 52 Shepherd JH, Spencer C, Herod J. et al Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer – cumulative pregnancy rate in a series of 123 women.. Brit J Obstet Gynaecol 2006; 113: 719-724 53 Marchiole P, Benchaib M, Buenerd A. et al Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy.. Gynecol Oncol 2007; 106: 132-141 54 Dursun P, LeBlanc E, Nogueira MC. Radical vaginal trachelectomy (Dargent's operation): a critical review of the literature.. Eur J S. 2007; 33: 933-941 55 Shepherd JH, Ind T, Tozer A. Fertility preservation surgery for early stage cervical cancer: lessons learned.. Gynecol Oncol 2008; 108: 63-63 56 Wright JD, Grigsby PW, Brooks R. et al Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy.. Cancer 2007; 110: 1281-1286 57 Stegemann M, Louwen M, van der Velden J. et al The incidence of parametrial tumor involvement in selected patients with early cervix cancer is too low to justify parametrectomy.. Gynecol Oncol 2007; 105: 475-480 58 Rob L, Charvat M, Robova H. et al Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer.. Int J Gynecol Cancer 2007; 17: 304-310 59 Altgassen C, Altgassen C, Hertel H. et al Multicenter validitation study of the sentinel lymph node concept in cervical cancer: AGO study group.. J Clin Oncol 2008; 26: 2943-2951 60 Wertheim E. The extended abdominal operation for carcinoma uteri.. Am J Obstet Gynecol 1912; 6: 169-232 61 Schauta F. Die erweiterte vaginale Totaloperation des Uterus beim Collumkarzinom.. Wien J Safar 1908 62 Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer.. Obstet Gynecol 1974; 44: 265-272 63 Querleu D, Morrow CP. Classification of radical hysterectomy.. Lancet Oncol 2008; 9: 297-303 64 Hertel H, Schneider A, Altgassen C, Hillemanns P. Zervixkarzinom.. Gynäkologe 2008; 41: 355-360 65 Zakashansky K, Bradley WH, Nezhat FR. New techniques in radical hysterectomy.. Curr Opinion Obstet Gynecol 2008; 20: 14-19 66 Höckel M. Totale mesometriale Resektion.. Gynäkologe 2008; 41: 361-368 67 Yabuki Y, Asamoto A, Hoshiba T. et al Radical hysterectomy: an anatomic evaluation of parametrial dissection.. Gynecol Oncol 2000; 77: 155-163 68 Frumovitz M, dos Reis R, Sun CC. et al Comparison of total laparoscopic radical hysterectomy and abdominal radical hysterectomy for patients with early-stage cervical cancer.. Obstet Gynecol 2007; 110: 96-102 69 Ghezzi F, Cromi A, Ciravolo G. et al Surgicopathologic outcome of laparoscopic versus open radical hysterectomy.. Gynecol Oncol 2007; 106: 502-506 70 Li G, Yan X, Shang H. et al A comparison of laparoscopic radical hysterectomy and pelvic lymphadenectomy and laparotomy in the treatment of I b–II a cervical cancer.. Gynecol Oncol 2007; 105: 176-180 71 Steed H, Rosen B, Murphy J. et al A comparison of laparoscopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer.. Gynecol Oncol 2004; 93: 588-593 72 Uccella S, Laterza R, Ciravolo G. et al A comparison of urinary complications following total laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy to open abdominal surgery.. Gynecol Oncol 2007; 107: 47-149 73 Boggess J. Robotic surgery in gynecologic oncology: evolution of a new surgical paradigm.. J Robotic Surg 2007; 1: 31-37 74 Köhler C, Tozzi R, Possover M. et al Explorative laparoscopy prior to exenterative surgery.. Gynecol Oncol 2002; 86: 311-315 75 Marnitz S, Köhler C, Müller M. et al Indications for primary and secondary exenterations in patients with cervical cancer.. Gynecol Oncol 2006; 103: 1023-1030 76 Marnitz S, Dowdy S, Lanowska M. et al Exenterations 60 years after first description – results of a survey among US and German gynecologic oncology centres.. Int J Gynecol Oncol 2008; [submitted] 77 Whitney CW, Sause W, Bundy BN. et al Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage II B–IV A carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.. J Clin Oncol 1999; 17: 1339-1348 78 Rose PG, Bundy BN, Watkins EB. et al Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.. N Engl J Med 1999; 340: 1144-1153 79 Stehman FB, Bundy BN, Kucera PR. et al Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I–II trial of the Gynecologic Oncology Group.. Gynecol Oncol 1997; 66: 262-267 80 Pearcey R, Brundage M, Drouin P. et al Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.. J Clin Oncol 2002; 20: 966-972 81 Morris M, Eifel PJ, Lu J. et al Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.. N Engl J Med. 1999; 340: 1137-1143 82 Stehman FB, Ali S, Keys HM. et al Radiation therapy with or without weekly cisplatin for bulky stage 1 B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.. Am J Obstet Gynecol 2007; 197: 503-506 83 Green J, Kirwan J, Tierney J. et al Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.. Cochrane Database Syst Rev 2005; 3: CD002225-CD002225 84 Keys HM, Bundy BN, Stehman FB. et al Gynecologic Oncology Group. Radiation therapy with and without extrafascial hysterectomy for bulky stage I B cervical carcinoma: a randomized trial of the Gynecologic Oncology Group.. Gynecol Oncol 2003; 89: 343-353 85 Rose PG, Ali S, Watkins E. et al Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.. J Clin Oncol 2007; 25: 2804-2810 86 Therapieempfehlungen des National Cancer Institut zum Zervixkarzinom.. www.cancer.gov 87 Pötter R, Dimopoulos J, Georg P. et al Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.. Radiother Oncol 2007; 83: 148-155 88 Moore KN, Gold MA, McMeekin DS. et al Vesicovaginal fistula formation in patients with Stage IV A cervial cancer.. Gyn Oncol 2007; 106: 498-501 89 Rotman M, Pajak TF, Choi K. et al Prophylactic extendedfield irradiation of para-aortic lymph nodes in stages II B and bulky I B and II A cervical carcinomas. Ten-year treatment results of RTOG 79–20.. J Amer Med Assoc 1995; 274: 387-393 90 Haie C, Pejovic MH, Gerbaulet A. et al Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group.. Radiother Oncol 1988; 11: 101-112 91 Small WJr, Winter K, Levenback C. et al Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116.. Int J Radiat Oncol Biol Phys 2007; 68: 1081-1087 92 Perez CA, Grigsby PW, Chao KS. et al Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix.. Int J Radiat Oncol Biol Phys 1998; 41: 307-317 93 Eifel PJ, Thoms WW, Smith TL. et al The relationship between brachytherapy dose and outcome in patients with bulky endocervical tumors treated with radiation alone.. Int J Radiat Oncol Biol Phys 1994; 28: 113-118 94 Lanciano RM, Won M, Coia LR. et al Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies.. Int J Radiat Oncol Biol Phys 1991; 20: 667-676 95 Girinsky T, Rey A, Roche B. et al Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome.. Int J Radiat Oncol Biol Phys 1993; 27: 1051-1056 96 Fyles A, Keane TJ, Barton M. et al The effect of treatment duration in the local control of cervix cancer.. Radiother Oncol 1992; 25: 273-279 97 Lanciano RM, Pajak TF, Martz K. et al The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patternsof-care study.. Int J Radiat Oncol Biol Phys 1993; 25: 391-397 98 Petereit DG, Sarkaria JN, Chappell R. et al The adverse effect of treatment prolongation in cervical carcinoma.. Int J Radiat Oncol Biol Phys 1995; 32: 1301-1307 99 Chen MF, Tseng CJ, Tseng CC. et al Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy.. Int J Radiat Oncol Biol Phys 2007; 67: 1438-1444 100 Beriwal S, Gan GN, Heron DE. et al Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.. Int J Radiat Oncol Biol Phys 2007; 68: 166-171 101 Salama JK, Mundt AJ, Roeske J. et al Preliminary outcome and toxicity report of extended-field, intensitymodulated radiation therapy for gynecologic malignancies.. Int J Radiat Oncol Biol Phys 2006; 65: 1170-1176 102 Huang KG, Lee CL, Tsai CS. et al A new approach for laparoscopic ovarian transposition before pelvic irradiation.. Gynecol Oncol 2007; 105: 234-237 103 Toki N, Tsukamoto N, Kaku T. et al Microscopic ovarian metastasis of the uterine cervical cancer.. Gynecol Oncol 1991; 41: 46-51 104 Yamamoto R, Okamoto K, Yukiharu T. et al A study of risk factors for ovarian metastases in stage I b–III b cervical carcinoma and analysis of ovarian function after a transposition.. Gynecol Oncol 2001; 82: 312-316 105 Veerasarn V, Lorvidhaya V, Kamnerdsupaphon P. et al A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results.. Gynecol Oncol 2007; 104: 15-23 106 Kim YS, Shin SS, Nam JH. et al Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.. Gynecol Oncol 2008; 108: 195-200 107 Kirwan JM, Symonds P, Green JA. et al A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer.. Radiother Oncol 2003; 68: 217-226 108 Matthews KS, Rocconi RP, Straughn JM. Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report.. Gynecol Oncol 2007; 106: 265-267 109 Marnitz S, Köhler C, Füller J. et al Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer.. Strahlenther Onkol 2006; 182: 45-51 110 Lerouge D, Touboul E, Lefranc JP. et al Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages I B2, II A, and II B with proximal parametrial invasion.. Cancer Radiother 2004; 8: 168-177 111 Modarress M, Maghami FQ, Golnavaz M. et al Comparative study of chemoradiation and neoadjuvant chemotherapy effects before radical hysterectomy in stage I B–II B bulky cervical cancer and with tumor diameter greater than 4 cm.. Int J Gynecol Cancer 2005; 15: 483-488 112 Petsuksiri J, Chansilpa Y, Therasakvichya S. et al Treatment options in bulky stage I B cervical carcinoma.. Int J Gynecol Cancer 2008; in press 113 Darus CJ, Callahan MB, Nguyen QN. et al Chemoradiation with and without adjuvant extrafascial hysterectomy for I B2 cervical carcinoma.. Int J Gynecol Cancer 2007; [E-pub ahead of print] 114 Bonomi P, Blessing JA, Stehman FB. et al Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.. J Clin Oncol 1985; 3: 1079-1085 115 Thiepgen T. The role of chemotherapy in the management of carcinoma of the cervix.. Cancer J 2003; 9: 425-425 116 McGuire WP, Blessing JA, Moore D. et al Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.. J Clin Oncol 1996; 14: 792-795 117 Morris M, Brader KR, Levenback C. et al Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.. J Clin Oncol 1998; 16: 1094-1098 118 Muderspach LI, Blessing JA, Levenback C. et al A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.. Gynecol Oncol 2001; 81: 213-215 119 Brader KR, Morris M, Levenback C. et al Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design.. J Clin Oncol 1998; 16: 1879-1884 120 Omura GA, Blessing JA, Vaccarello L. et al Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.. J Clin Oncol 1997; 15: 165-171 121 Moore DH, Blessing JA, McQuellon RP. et al Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.. J Clin Oncol 2004; 22: 3113-3119 122 Long HJ, Bundy BN, Grendys EC. et al Gynecologic Oncology Group study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.. J Clin Oncol 2005; 23: 4626-4633 123 Monk BJ, Huang HQ, Cella D. et al Gynecologic Oncology Group study. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study.. J Clin Oncol 2005; 23: 4617-4625 124 Monk BJ, Sill M, McMeekin DS. et al A randomized phase III trial of four cisplatin containing doublet combinations in stage IV B, recurrent or persistent cervical cancer: a Gynecologic Oncology Group (GOG) study.. J Clin Oncol 2008; 26 (suppl): 5504-5504 125 Landoni F, Maneo A, Colombo A. et al Randomised study of radical surgery versus radiotherapy for stage I b–II a cervical cancer.. Lancet 1997; 350: 535-540
